Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine

Human Vaccines

Volumn 6, Issue 4, 2010, Pages 297-308

  Okada, Masaji ^a   Kita, Yoko ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

CTL; MDR TB therapy; Monkey; Recombinant DNA

Indexed keywords

ADJUVANT; AERAS 402 DNA VACCINE; BCG VACCINE; DNA VACCINE; GRANULYSIN; HEAT SHOCK PROTEIN 65; HSP65 IL 2 DNA VACCINE; INTERLEUKIN 12; LIPOCALIN2 DNA VACCINE; MPT51DNA VACCINE; MTB72F VACCINE; MVA85A DNA VACCINE; MYCOBACTERIUM ANTIGEN; RECOMBINANT BCG VACCINE; SECRETORY LEUKOCYTE PROTEASE INHIBITORY PROTEIN DNA VACCINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; BODY WEIGHT; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; DRUG EFFICACY; GUINEA PIG; HUMAN; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; MONKEY; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROPHYLAXIS; REVACCINATION; REVIEW; SCID MOUSE; SURVIVAL; TUBERCULOSIS; VACCINE PRODUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; MACACA FASCICULARIS; MICE; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES, CYTOTOXIC; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 77950664932     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.4.10172     Document Type: Review

References (111)

1. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267-70.
2. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191-204. (Pubitemid 43202265)
3. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129.
4. Hess J, Schaible U, Raupach B, Kaufmann SH. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv Immunol 2000; 75:1-88. (Pubitemid 30436841)
5. + T cells in HLA-transgenic mice and humans. J Immunol 2000; 165:6463-71.
6. + T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998; 95:270-5.
7. Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003; 21:29-70. (Pubitemid 37174526)
8. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 2002; 70:1623-6.
9. Srivastava IK, Liu MA. Gene vaccines. Ann Intern Med 2003; 138:550-9.
10. Okada M, Kishimoto T, editors. The potential application and limitation of cytokine/growth factor manipulation in cancer therapy. In "Cell proliferation in Cancer: Regulatory Mechanisms of Neoplastic Cell Growth" (Ed.,) Pusztai L, Lewis C, Yap E: Oxford University Press 1996; 218-44.
11. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19:764-78.
12. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18:1893-901.
13. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 2004; 199:126-43.
14. Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin Immunol 1999; 90:100-7.
15. Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971-8.
16. Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999; 1:30-3.
17. Orme IM. The search for new vaccines against tuberculosis. J Leukoc Biol 2001; 70:1-10. (Pubitemid 32613656)
18. Doherty TM, Andersen P. Tuberculosis vaccine development. Curr Opin Pulm Med 2002; 8:183-7.
19. McMurray DM. Guinea pig model of tuberculosis, 113-134. In Bloom BR (ed), Tuberculosis: pathogenesis, protection and control. ASM Press, Washington, DC 1994.
20. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomologus monkey model of TB. Vaccine 2007; 25:2990-3.
21. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5.
22. Hoft D. Tuberculosis vaccine development: goals, immunological design and evaluation. Lancet 2008; 372:164-75.
23. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742-51.
24. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43.
25. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995; 58:417-54.
26. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13:399-415.
27. Okada M, Takemoto Y, Okuno Y, Hashimoto S, Yoshida S, Fukunaga Y, et al. The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine 2005; 23:2269-72.
28. Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007; 25:3038-40.
29. Rook GAW, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: Is there a common pathway activated by effective protocols. J Infectious Diseases 2007; 196:191-8.
30. Mitsuyama M, McMurray DN. Tuberculosis: vaccine and drug development. Tuberculosis 2007; 87:10-3.
31. Andersen P. Tuberculosis vaccines - an update. Nature Reviews Microbiology 2007; 5:484-7.
32. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2:893-8.
33. Ulmer JB, Liu MA, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, et al. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997; 15:792-4.
34. Baldwin SL, D'Souza C, Roberts AD, Kelly BP, Frank AA, Lui MA, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998; 66:2951-9.
35. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999; 67:1702-7.
36. Skeiky YA, Ovendale PJ, Jen S, Alderson MR, Dillon DC, Smith S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000; 165:7140-9.
37. Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999; 67:2941-50.
38. Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000; 18:2155-63.
39. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400:269-71.
40. Tanghe A, Lefèvre P, Denis O, D'Souza S, Braibant M, Lozes E, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999; 162:1113-9.
41. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68:791-5.
42. Fonseca DP, Benaissa-Trouw B, van Engelen M, Kraaijeveld CA, Snippe H, Verheul AF. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein. Infect Immun 2001; 69:4839-45.
43. Delogu G, Brennan MJ. Comparative immune response to PE and PE-PGRS antigens of Mycobacterium tuberculosis. Infect Immun 2001; 69:5606-11.
44. Khera A, Singh R, Shakila H, Rao V, Dhar N, Narayanan PR, et al. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine 2005; 23:5655-65.
45. Delogu G, Li A, Repique C, Collins F, Morris SL. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 2002; 70:292-302. (Pubitemid 34028630)
46. Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004; 23:780-8.
47. Tanghe A, Denis O, Lambrecht B, Motte V, van den Berg T, Huygen K. Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect Immun 2000; 68:3854-60.
48. Franco LH, Wowk PF, Silva CL, Trombone AP, Coelho-Castelo AA, Oliver C, et al. A DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells. Genet Vaccines Ther 2008; 6:3.
49. Gurunathan S, Klinman DM, Sender RA. DNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000; 18:927-74.
50. Laddy DJ, Weiner DB. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 2006; 25:99-123. (Pubitemid 44034576)
51. Ishii KJ, Akira S. Innate immune recognition of, and regulation by DNA. Trends Immunol 2006; 27:525-32.
52. Zelenay S, Elias F, Flo J. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. Eur J Immuol 2003; 33:1382-92.
53. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000; 192:595-600.
54. Takeshita F, Ishii KJ, Ueda A, Ishigatsubo Y, Klinman DM. Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression. Eur J Immunol 2000; 30:108-16. (Pubitemid 30011771)
55. Takeshita F, Klinman DM. CpG ODN-mediated regulation of IL-12 p40 transcription. Eur J Immunol 2000; 30:1967-76. (Pubitemid 30456193)
56. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, et al. Cutting edge: a novel Toll/IL-I receptor domain-containg adapter that preferentially activates the IFNbeta promoter in the Toll-like receptor signaling. J Immunol 2002; 169:6668-72.
57. Rosada RS, Torre LG, Frantz FG, Trombone A PF, Zarate Blades CR, Fonseca DM, et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunology 2008; 9:38.
58. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends in molecular medicine 2006; 12:216-72.
59. Okada M, Tanaka T, Yoshida S, Kita Y, Kanamaru N, Hashimoto S, et al. Novel vaccination (HVJ-liposome/HSP65 + IL-12 DNA and recombinant 72f BCG) against tuberculosis using cynomolgus monkey. US-Japan Cooperative Medical Science Program. Fortieth Tuberculosis and Leprosy Research Conference (Seattle USA) 2005; 46-56.
60. Miki K, Nagato T, Tanaka T, Kim Y-H, Uchijima M, Ohara M, et al. Induction of protective cellular immunity against M. tuberculosis by attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic plasmid for antigen 85 complex and MPB/MPT51. Infect Immun 2004; 72:2014-21.
61. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosters BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med 2008; 10:1240-4.
62. Dietrich J, Billeskov R, Doherty TM, Andersen P. Synergistic effect of bacillus Calmette Guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol 2007; 178:3721-30.
63. Mata-Hara V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant Monophosphory Lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316:1628-32.
64. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6.
65. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133-41.
66. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-9.
67. Okada M, Klimpel GR, Kuppers RC, Henney CS. The differentiation of cytotoxic T cells in vitro I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol 1979; 122:2527-33.
68. Okada M, Kishimoto T, Igarashi T, Teranishi T, Yamamura Y. LPS- or 8Br-cyclic AMP-induced production of T cell-activating factor(s) in macrophage tumor cell line J774.1. J Immunol 1978; 120:1097-101.
69. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci USA 1981; 78:7717-21.
70. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90.
71. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172:7618-28.
72. + T cells? J Clin Invest 2007; 117:2092-4.
73. + T cell and their role in immunity. Crit Rev Immunol 2006; 26:317-52.
74. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689-98.
75. Igarashi T, Okada M, Azuma I, Yamamura Y. Adjuvant activity of synthetic N-acetyl-muramyl-L-alanyl-D-isoglutamine and related compounds on cell-mediated cytotoxicity in syngeneic mice. Cell Immunol 1977; 34:270-8.
76. Coulombe F, Dirangahi M, Veyrier F, Leseleuc L, Gleason JL, Yang Y, et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 2009; 206:1709-16.
77. + T cells provides a host defense mechanism against Mycobacterium tuberculosis. J Immunol 2005; 175:7474-83.
78. + T cell in healthy contacts of tuberculosis. Immunology 1998; 95:585-90.
79. + T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol 2001; 166:439-46.
80. Carraza C, Juarez E, Torres M, Ellner JJ, Sada E, Schwander SK. Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. Am J Respir Crit Care Med 2006; 174:238-45.
81. Tully G, Kortsik C, Höhn H, Zehbe I, Hitzler WE, Neukirch C, et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol 2005; 174:2174-84.
82. Kita Y, Kanamaru N, Hashimoto S, Nishida Y, Nakatani H, Takao K, et al. The study of Nobel vaccination using granulysin transgenic mice. Sixth World Congress on Vaccines, Immunization and Immunotherapy 2008; 39.
83. Pena SV, Hanson DA, Carr BA, Goralski TJ, Krensky M. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol 1997; 158:2680-8.
84. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediatd by granulysin. Science 1998; 282:121-5.
85. Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol 2007; 178:77-84. (Pubitemid 46033589)
86. Okada M, Tanaka T, Inoue Y, Yoshida S, Ohara N, Yamada T, et al. New (DNA-, recombinant BCG- and subunit-) vacctination against tuberculosis and cytotoxic activity. US-Japan Cooperatie Medical Science Program. Thirty-six Tuberculosis and Leprosy Research Conference (New Orleans USA) 2001; 127-33.
87. Bruns H, Meinken C, Schanenberg P, Harter G, Kern P, Modlin RL, et al. Anti-TNF immunotherapy reduces CD8+ cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119:1167-77.
88. Campbell JJ, Murphy KE, Kunkel EJ, Brightling CE, Soler D, Shen Z, et al. CCR7 expression and memory T cell diversity in humans. J Immunol 2001; 166:877-84.
89. Geglnat J, Sallusto F, Lanzavecchua A. Cytokinedriven proliferation and differentiation of human naïve, central memory and effector memory CD4(+) T cells. J Exp Med 2001; 194:1711-9.
90. Schuns KS, Lefrancois L. Cytokine control of memory T cell development and survival. Nat Rev Immunol 2003; 3:269-79.
91. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Harwitz MA. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG: Infection and Immunity 2008; 76:5200-14.
92. Kaneda Y. Applications of Hamagglatinating Virus of Japan in therapeutic delivery systems. Expert Opin Drug Deliv 2008; 5:221-33.
93. Yoshida A, Inagawa H, Kohchi C, Hino M, Ito F, Tomoda K, et al. Selective delivery of rifampicin incorporated into poly (DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guette-Guerin. Antimicrobial Agents and Chemotherapy (in press).
94. Hanekom WA, Dockrell HM, Ottenhoff THM, Doherty TM, Fletcher H, McShane H, et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendation. PLos Medicine 2008; 5:145.
95. Aoshi T, Nagato T, Suzuki M, Uchijima M, Hashimoto D, Rafiei A, et al. Identification of an HLA-A0201-restricted T-cell epitope on the MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis, by MPT51 overlapping peptide screening. Infect and Immunity 2008; 7:1565-91.
96. Saiga H, Nishimura J, Kuwata H, Okuyama M, Matsumoto S, Sato S, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol 2008; 81:521-7.
97. Nishimura J, Saiga H, Sato S, Okuyama M, Kayama H, Kuwata H, et al. Potent antimycobacterial activity of mouse secretory leukocyte protease inhibitor. J Immunol 2008; 180:4032-9.
98. Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, et al. Cloning expression and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 1999; 67:3998-4007.
99. Reed S, Alderson MR, Dalemans W, Lobet Y, Skeiky YA. Prospects for a better vaccine against tuberculosis. Tuberculosis 2003; 83:213-9.
100. Hussey G. Prospects for new tuberculosis vaccines. SAMJ 2007; 97:1001-2.
101. Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whela KT, Alder NC, et al. Boosting BCG vaccination with MVA85A domn-regulates the immunoregulatory cytokine TGFβ1. Vaccine 2008; 26:5264-75.
102. Brooks RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in west Africa. Plos one 2008; 3:2921.
103. th International Conference on Emerging Infection Diseased in the pacific Rim 2005; 23-4.
104. Kaufmann SH. Recent finding in immunology give tuberculosis vaccines a new booster. Trends Immunol 2005; 26:660-7.
105. Horwitz MA, Harth G. A new vaccine against tuberculosis affords grater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003; 71:1672-9.
106. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine against tuberculosis of recombinant Mycobacterium bovis bacilli Camett-Guerin mutants that secrete listeriolysin. J Clin Invest 2005; 115:2472-9.
107. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006; 24:105-17.
108. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis polyprotein vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332-9.
109. Ibanga HB, Brookes RH, Hill PC, Owaife PK, Fletcher HA, Leinhardt C, et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 2006; 6:522-8.
110. Sadoff JC, Hone D. The role of "go no-go" decisions in TB vaccine development. Microbes Infect 2005; 7:899-904.
111. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59-64. (Pubitemid 38997752)